2169 Background: MET amplification in NSCLC was correlated with acquired resistance to EGFR TKIs, gefitinib and erlotinib. The aim of this study was to investigate whether MET is amplified in NSCLC prior to TKIs therapy and examine the association of MET amplification with EGFR copy number, mutation status and responsiveness to TKIs. Methods: Amplification levels of MET and EGFR genes were determined in FFPE tumor DNA of known EGFR and K-RAS mutation status from 69 patients with advanced NSCLC treated with gefitinib. Quantitative real-time PCR was performed to analyse MET (7q31.2) and EGFR (7p12) gene copy numbers relative to a reference, the TOP3A (17p12-p11.2) gene. Relative copy numbers of the EGFR and MET genes were expressed as the ratio of PCR signals obtained for EGFR or MET and TOP3A . The cutoff for normal copy numbers was established as the 95% confidence upper limit (mean + 1.96 standard deviations) of EGFR/TOP3A and MET/TOP3A determined in DNA of normal matched tissue from 14 patients respectively. Results: Seven (10%) of the 69 primary tumors exhibited increased MET copy number. None of these tumors had an EGFR mutation whereas 3 of them had K-RAS mutation. No significant association was found between MET copy number and TKI-related disease control rate or survival. Among the 7 patients showing MET amplification 2 (28.5%) with EGFR wild type mutation status exhibited progressive disease. EGFR amplification was detected in 5 (7.2%) patients and among them one (20%) showed MET amplification as well. Response rate was not associated with the EGFR amplification. One patient with a Del19 EGFR mutation reached partial response and another one with wild type mutation status achieved stable disease. The patient showing EGFR and MET amplification had not EGFR and K-RAS mutations and exhibited progressive disease. Conclusions : Met amplification is not a common event in NSCLC prior to EGFR TKIs therapy. However the predictive value of chromosome 7 polysomy should be considered with caution.